In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme Corp.

Division of Sanofi
www.genzyme.com

Latest From Genzyme Corp.

Finance Watch: Government Grants Galore And Other New Funding Sources

While Forbion's new €360m venture capital fund and other investors have emerged to fund private and public companies, BARDA and other US agencies have been active supporters of biopharma firms in recent weeks. Also, KSQ grabs $80m in VC cash and VelosBios brings in $50m.

Financing StartUps and SMEs

Partnering In Cell And Gene Therapy Is A Unique Endeavor

Industry and academic representatives shared viewpoints at Biotech Week Boston in September 2018, including what is unique about deal-making in the cell and gene field.

Regenerative Medicine Deals

FDA Scientists Give Leadership High Marks; Some Worry About Industry Influence

Union of Concerned Scientists' survey finds 65% of 354 respondents feel their direct supervisors back them on politically contentious positions; Commissioner Gottlieb gets glowing reviews.

FDA BioPharmaceutical

Quiet Riot? Gene Silencing Candidates Still Ready To Make Noise In Lipid Disorders

Despite complete response letter for Akcea's Waylivra, RNA therapeutics may have regulatory pathway to approval for lipid disorders.

Drug Approval Standards Cardiovascular
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register